FLT3 and acute myeloid leukemia: (2) The addition of fms-like tyrosine kinase 3 (FLT3) inhibitors (gilteritinib, midostaurin, sorafenib, quizartinib, crenolanib, others) to intensive chemotherapy, or to HMA/low-intensity therapy in FLT3-mutated AML.